Form 4: Vera Therapeutics Director, Andrew Cheng, Acquires 14,000 Stock Options

Director Andrew Cheng acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Summary

• On May 14, 2025, Andrew Cheng, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
• The exercise price of these options is $21.19.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through the date of such change in control.
• The options expire on May 13, 2035.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard insider transaction filing and doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.

Stakeholder Impact

• The acquisition of stock options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.

Key Dates

Keywords

Vera Therapeutics, Stock Options, Form 4, Director, Beneficial Ownership, Cheng Andrew